Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer
This study has been terminated.
(The results of the dose escalation phase did not identify a well-tolerated dose that would permit further study in Phase 2.)
Kyowa Hakko Kirin Pharma, Inc.
First Posted: September 10, 2010
Last Update Posted: April 6, 2016
Information provided by (Responsible Party):
Kyowa Kirin Pharmaceutical Development, Inc. ( Kyowa Hakko Kirin Pharma, Inc. )
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been terminated.|
|Study Completion Date:||December 2012|
|Primary Completion Date:||December 2012 (Final data collection date for primary outcome measure)|
Dickson MA, P. LoRusso P, E. A. Sausville EA, Rao N, Kobayashi E, Kurman MR, Akinaga S, Schwartz GK. Open-label, sequential, ascending, multi-dose, phase I study of KW-2450 as monotherapy in subjects with previously treated advanced solid tumors. J Clin Oncol 29: 2011 (suppl; abstr 3078)